muMab 4901

muMab 4901 is a **monoclonal antibody** that selectively binds to and blocks the function of **calcitonin gene-related peptide** (CGRP), with high affinity for rat αCGRP[1][7]. By inhibiting CGRP, muMab 4901 effectively suppresses neurogenic vasodilatation, as demonstrated in preclinical rat models. A single administration of muMab 4901 produces a long-lasting blocking effect, inhibiting neurogenic vasodilatation for at least one week after dosing. It was developed and licensed from the University of California, Los Angeles (UCLA)[1]. muMab 4901 is primarily used in preclinical research to investigate CGRP-related mechanisms, such as those implicated in migraine pathogenesis. There is no evidence that muMab 4901 has been developed for or trialed in human therapy.

Other names

muMab 4901muMab4901muMab-4901